Pharmaceutical News

RSS

Geron bows out of stem cell research

Geron Corp. is removing itself from the field it pioneered – stem cell research. Late Monday, the company said it would halt its study of a stem cell-based treatment for spinal cord injury, the first embryonic stem cell trial approved in the U.S.

16 Nov 2011

Atherosclerotic plaques spread downstream in coronary arteries

In human coronary arteries, atherosclerotic plaques tend to spread downstream because of the changes in blood flow patterns the plaque causes, researchers have found.

16 Nov 2011

ZIOPHARM announces new preclinical data from two darinaparsin studies on solid tumors

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today new preclinical data from two separate studies of darinaparsin, a novel organic arsenic, in various solid tumor models at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

16 Nov 2011

Amgen receives EC approval to extend therapeutic indications for Vectibix

Amgen today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy.

16 Nov 2011

Advaxis licenses ISG15 tumor antigen from University of Pennsylvania

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has exclusively licensed the use of antigen ISG15 in Advaxis' Lm-LLO based immunotherapies from the University of Pennsylvania.

16 Nov 2011

Niacin not effective in reducing risk of stroke, heart attack in stable CV patients

In patients whose bad cholesterol is very well-controlled by statins for a long time period, the addition of high-dose, extended release niacin did not reduce the risk of cardiovascular events, including heart attack and stroke.

16 Nov 2011

Combination of antipsychotic and antidepressant drugs may increase risk of CV mortality

People taking anti-psychotic drugs and anti-depressant drugs have a much higher risk of dying during an acute coronary event of a fatal arrhythmia than the rest of the population, finds a Finnish study published in the European Heart Journal.

16 Nov 2011

International consortium develops first-in-class adiponectin receptor agonist

A compound that mimics the effects of adiponectin, a beneficial protein that is produced by fat tissue in healthy weight individuals and may exhibit protective effects against cancer, cardiovascular disease, inflammatory conditions and insulin resistance has been developed by an international consortium lead by Dr. Eva Surmacz, Associate Professor in Biology (Adjunct) and director of the Obesity and Cancer Program at the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University's College of Science and Technology.

16 Nov 2011

Evacetrapib drug may increase HDL-C and decrease LDL-C levels

Among patients with sub-optimal low-density lipoprotein cholesterol (LDL-C) or high-density lipoprotein cholesterol (HDL-C) levels, use of the drug evacetrapib alone or in combination with statin medications was associated with significant increases in HDL-C levels and decreases in LDL-C levels, according to a study appearing in the November 16 issue of JAMA, a theme issue on cardiovascular disease.

16 Nov 2011

Changing priorities for major generic drug producers could lead to rising drug prices in developing countries

This is Africa reports on how changing priorities for major generic drug producing countries, such as Brazil, India and China -- countries that "redefined affordable drugs, making access to medicines possible for millions in low-income regions" -- and greater adoption of intellectual property rules could reshape the African pharmaceutical landscape, potentially leading to price increases, according to some experts.

16 Nov 2011

Silibinin stops spread of lung cancer in mice

Tissue with wound-like conditions allows tumors to grow and spread. In mouse lung cancer cells, treatment with silibinin, a major component of milk thistle, removed the molecular billboards that signal these wound-like conditions and so stopped the spread of these lung cancers, according to a recent study published in the journal Molecular Carcinogenesis.

16 Nov 2011

EPO-secreting engineered vessels could reverse anemia

Patients who rely on recombinant, protein-based drugs must often endure frequent injections, often several times a week, or intravenous therapy. Researchers at Children's Hospital Boston demonstrate the possibility that blood vessels, made from genetically engineered cells, could secrete the drug on demand directly into the bloodstream.

15 Nov 2011

Pneumococcal vaccine Prevnar13 effective in seniors

Pneumococcal disease kills millions worldwide and the largest affected groups are children and the elderly. Federal health scientists now assure that the popular pneumococcal vaccine Prevnar is at least as effective as a rival vaccine at protecting adults from the sometimes-deadly infection.

15 Nov 2011

Xarelto (rivaroxaban) shows success as blood thinner in acute coronary syndrome

A new anti-blood clotting drug – Xarelto (rivaroxaban) has shown clinical success. It may help people with “acute coronary syndrome” lower their risk of death, subsequent heart attack or stroke, a new study finds. Acute coronary syndrome is term that includes people with angina or prior history of heart attack.

15 Nov 2011

Moberg Derma receives Vinnova grant to develop Limtop for actinic keratosis, genital warts

Moberg Derma AB has been granted 4 MSEK by Vinnova for the development of Limtop, an innovative formulation for the treatment of actinic keratosis, genital warts and basal cell cancer.

15 Nov 2011

Scil Proteins completes manufacturing agreement with Lundbeck

Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, announced today the successful completion of a manufacturing agreement for Lundbeck, an international pharmaceutical company specializing in central nervous system disorders.

15 Nov 2011

Long-term AED therapy may increase risk of atherosclerosis in epilepsy patients

New research reveals that patients with epilepsy who were treated for extended periods with older generation antiepileptic drugs (AEDs) may be at increased risk for developing atherosclerosis, a common disorder known as hardening of the arteries.

15 Nov 2011

Tigecycline antibiotic shows promise against leukemia

Clinician-scientists in the Princess Margaret Cancer Program have found a promising approach to treating leukemia, using an old drug in a new way.

15 Nov 2011

Eliminating drug co-pays improves medication adherence in heart attack patients

The use of specific medications following a heart attack has been shown to reduce cardiovascular events and mortality, however; while highly effective, the rate of adherence to these medications is poor. Researchers from Brigham and Women's Hospital (BWH) evaluated whether eliminating co-payments for these medications would increase adherence and improve outcomes in patients who have had a heart attack.

15 Nov 2011

CDC launches new antibiotic tracking system

The Centers for Disease Control and Prevention is launching a new antibiotic tracking system allowing hospitals to monitor antibiotic use electronically, make better decisions about how to improve use, and compare themselves to other hospitals. Before now, CDC was only able to track antibiotic use in doctors' offices.

15 Nov 2011